Preventing Hospital-Associated Thrombosis (HAT)—Recommendations for extending venous thromboembolism (VTE) prophylaxis beyond the immediate duration of the hospital stay
Depending on the nature of surgery, VTE prophylaxis may be recommended beyond the duration of the hospital stay . This slide kit presents some of the clinical trial evidence that supports the Clexane® licence for extended thromboprophylaxis after some types of major surgery.
Clexane® is indicated for prophylaxis of venous thromboembolic disease in moderate and high risk surgical patients, in particular those undergoing orthopaedic or general surgery including cancer surgery . For major orthopaedic surgery, extended duration Clexane® thromboprophylaxis - at a dose of 4,000 IU (40 mg) given subcutaneously once daily (preferably started 12 hours before surgery) - is recommended for up to 5 weeks after major orthopaedic surgery, and up to 4 weeks after abdominal or pelvic surgery for cancer .